Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Amgen vs. TKT Matters

This article was originally published in Start Up

Executive Summary

Amgen's patent infringement lawsuit against Transkaryotic Therapies is probably the most important of its kind, and not merely because the product Amgen is trying to protect, erythropoietin, is the company's--and the biotech industry's--biggest revenue generator. This lawsuit, although not yet decided, already offers some valuable lessons both in developing a patent portfolio and defending a patented product.
Advertisement

Related Content

TKT: Victory At Last
TKT: Bloodied But Unbowed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC090169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel